It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version between February and March 2025.

Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...

In this photo is a Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. (Photographer: Shelby Knowles/Bloomberg) The anti-obesity drug Zepbound ...

FILE - Zepbound injection pen (Photographer: Shelby Knowles/Bloomberg via Getty Images) According to Eli Lilly, after one year, 42% of adults on Zepbound and 50% of adults on Zepbound with PAP ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

Eli Lilly estimates that is about 15-20 million adults in the U.S. An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, March 28, 2024. Obstructive sleep apnea ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Shelby Knowles/Bloomberg via Getty A Zepbound injection pen. The FDA has also cited overdoses as a concern, as it has received reports of patients giving themselves the incorrect dose of off-brand ...

tirzepatide — the active ingredient in Zepbound and its counterpart Mounjaro for diabetes — is fully available again. "FDA has determined that the shortage of tirzepatide injection products ...